Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Debt (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Total Debt for 6 consecutive years, with $4.6 million as the latest value for Q2 2017.

  • For Q2 2017, Total Debt fell 79.49% year-over-year to $4.6 million; the TTM value through Jun 2017 reached $4.6 million, down 79.49%, while the annual FY2016 figure was $14.7 million, 46.66% down from the prior year.
  • Total Debt hit $4.6 million in Q2 2017 for Corcept Therapeutics, down from $10.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $35.1 million in Q1 2014 and bottomed at $4.6 million in Q2 2017.
  • Average Total Debt over 5 years is $27.3 million, with a median of $32.1 million recorded in 2015.
  • Year-over-year, Total Debt grew 13.3% in 2013 and then plummeted 79.49% in 2017.
  • Corcept Therapeutics' Total Debt stood at $35.1 million in 2013, then decreased by 3.36% to $33.9 million in 2014, then decreased by 18.87% to $27.5 million in 2015, then tumbled by 46.66% to $14.7 million in 2016, then tumbled by 68.81% to $4.6 million in 2017.
  • According to Business Quant data, Total Debt over the past three periods came in at $4.6 million, $10.1 million, and $14.7 million for Q2 2017, Q1 2017, and Q4 2016 respectively.